WE HAVE 2 NEW TYSABRI EDITORS STARTING 4/15/10! THEY WIL BE POSTING TYSABRI NEWS EVERY DAY!
Wednesday, May 14
Analyst Sees Rising Sales for Biogen Idec
remains its top seller and it bought in $733 million in revenue, down
slightly from a year ago. The company also had $401 million in revenue
from Tysabri, a newer drug that treats MS and Crohn's disease, and $287
million from Tecfidera. READ MORE